The impact of microscopic disease on the tumor control probability in non-small-cell lung cancer.

PURPOSE To indicate which clinical target volume (CTV) margin (if any) is needed for an adequate treatment of non-small-cell lung cancer (NSCLC) using either 3D conformal or stereotactic radiotherapy, taking the distribution of the microscopic disease extension (MDE) into account. METHODS AND MATERIALS On the basis of the linear-quadratic biological model, a Monte-Carlo simulation was used to study the impact of MDE and setup deviations on the tumor control probability (TCP) after typical 3D conformal and stereotactic irradiation techniques. Setup deviations were properly accounted for in the planning target volume (PTV) margin. Previously measured distributions of MDE outside the macroscopic tumor in NSCLC patients were used. The dependence of the TCP on the CTV margins was quantified. RESULTS The presence of MDE had a demonstratable influence on the TCP in both the 3D conformal and the stereotactic technique when no CTV margins were employed. The impact of MDE on the TCP values was greater in the 3D conformal scenario (67% TCP with MDE; 84% TCP without MDE) than for stereotactic radiotherapy (91% TCP with MDE; 100% TCP without MDE). Accordingly, an increase of the CTV margin had the greatest impact for the 3D conformal technique. Larger setup errors, with appropriate PTV margins, lead to an increase in TCP for both techniques, showing the interdependence of CTV and PTV margins. CONCLUSIONS MDE may not always be eradicated by the beam penumbra or existing PTV margins using either 3D conformal or stereotactic radiotherapy. Nonetheless, TCP modeling indicates an overall local control rate above 90% for the stereotactic technique, while a non-zero CTV margin is recommended for better local control of MDE when using the 3D conformal technique.

[1]  J C Stroom,et al.  Inclusion of geometrical uncertainties in radiotherapy treatment planning by means of coverage probability. , 1999, International journal of radiation oncology, biology, physics.

[2]  E. Smit,et al.  Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.

[3]  Kurt Baier,et al.  Dose-response in stereotactic irradiation of lung tumors. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  M. Mehta,et al.  Dose coverage beyond the gross tumor volume for various stereotactic body radiotherapy planning techniques reporting similar control rates for stage I non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.

[5]  P. Lambin,et al.  The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  Lei Xing,et al.  Stereotactic body radiation therapy in multiple organ sites. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Fowler,et al.  The Effect of Multiple Small Doses of X Rays on Skin Reactions in the Mouse and a Basic Interpretation , 1976, Radiation research.

[8]  L. Xing,et al.  Optimization of radiotherapy dose-time fractionation with consideration of tumor specific biology. , 2005, Medical physics.

[9]  James Bedford,et al.  Defining the margins in the radical radiotherapy of non-small cell lung cancer (NSCLC) with active breathing control (ABC) and the effect on physical lung parameters. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  M. V. van Herk,et al.  The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy. , 2000, International journal of radiation oncology, biology, physics.

[11]  Liesbeth Boersma,et al.  Microscopic disease extension in three dimensions for non-small-cell lung cancer: development of a prediction model using pathology-validated positron emission tomography and computed tomography features. , 2012, International journal of radiation oncology, biology, physics.

[12]  J C Rosenwald,et al.  Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. , 2000, International journal of radiation oncology, biology, physics.

[13]  Marnix G Witte,et al.  The effects of target size and tissue density on the minimum margin required for random errors. , 2004, Medical physics.

[14]  L. Boersma,et al.  First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  Joos V Lebesque,et al.  Inclusion of geometric uncertainties in treatment plan evaluation. , 2002, International journal of radiation oncology, biology, physics.